Objective:To calculate the relative biological effectiveness (RBE) value of the released low-energy electrons in gadolinium neutron capture therapy ( 157GdNCT) based on microdosimetry. Methods:The Monte Carlo (MC) code Geant4-DNA package was used to simulate the energy deposition distribution and microdosimetry parameters of low-energy electrons released during gadolinium neutron capture treatment in different sensitive target volumes and physical models on track structures. On this basis, RBE value was obtained based on the microdosimetry kinetic model (MKM).Results:The low-energy electron RBE value was highly variable in different sensitive target volumes and decreases with increasing sensitive target volumes. With 6-nm-diameter sensitive target as reference, RBE value was 1.77 for 6-nm diameter, 1.53 for 10 nm diameter with percentage difference 13%, and 1.40 for 15-nm diameter with percentage difference of 21%, respectively. The effect of different Geant4-DNA physical models on the RBE of low-energy electrons was small. Using the RBE value of 1.53 for physical model option2 as reference, the RBE values of option6 and option7 were 1.49 and 1.52, respectively, with the percentage differences of 2.6% and 0.6%, respectively.Conclusions:The RBE values of low energy electrons released by 157GdNCT in different sensitive target volumes and physical models were calculated by MKM to be 1.40-1.77.

Brain metastasis is a common and serious complication of breast cancer, which is commonly associated with poor survival and prognosis. In particular, the treatment of brain metastasis from triple-negative breast cancer (BM-TNBC) has to face the distinct therapeutic challenges from tumor heterogeneity, circulating tumor cells (CTCs), blood-brain barrier (BBB) and blood-tumor barrier (BTB), which is in unmet clinical needs. Herein, combining with the advantages of synthetic and natural targeting moieties, we develop a "Y-shaped" peptide pVAP-decorated platelet-hybrid liposome drug delivery system to address the all-stage targeted drug delivery for the whole progression of BM-TNBC. Inherited from the activated platelet, the hybrid liposomes still retain the native affinity toward CTCs. Further, the peptide-mediated targeting to breast cancer cells and transport across BBB/BTB are demonstrated in vitro and in vivo. The resultant delivery platform significantly improves the drug accumulation both in orthotopic breast tumors and brain metastatic lesions, and eventually exhibits an outperformance in the inhibition of BM-TNBC compared with the free drug. Overall, this work provides a promising prospect for the comprehensive treatment of BM-TNBC, which could be generalized to other cell types or used in imaging platforms in the future.

AL3810, a molecular dual inhibitor of the vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), has earned the permission of phase II clinical trial for tumor treatment by China FDA. As a reversible ATP-competitive inhibitor, AL3810 targets ATP-binding site on intracellular region of VEGFR and FGFR, whereas, AL3810 lacking interplay with extracellular region of receptors rendered deficient blood-brain tumor barrier (BBTB) recognition, poor brain penetration and unsatisfactory anti-glioma efficacy. Integrin

The dense extracellular matrix and high interstitial fluid pressure of tumor tissues prevent the ability of anti-tumor agents to penetrate deep into the tumor parenchyma for treatment effects. C-end rule (CendR) peptides can enhance the permeability of tumor blood vessels and tumor tissues binding to neuropilin-1 (NRP-1), thus aiding in drug delivery. In this study, we selected one of the CendR peptides (sequence RGERPPR) as the parent l-peptide and substituted d-amino acids for the l-amino acids to synthesize its inverso peptide (RGERPPR). We investigated the NRP-1 binding activity and tumor-penetrating ability of (RGERPPR). We found that the binding affinity of (RGERPPR) with NRP-1 and the cellular uptake was significantly higher than that of RGERPPR. Evans Blue tests revealed that (RGERPPR) exhibited improved tumor-penetrating ability in C6, U87 and A549 tumor-bearing nude mice. Using nude mice bearing A549 xenograft tumors as a model, we found that the rate of tumor growth in the group co-administered with (RGERPPR) and gemcitabine (Gem) was significantly lower than the gemcitabine-treated group with a tumor suppression rate (TSR%) of 55.4%. Together, our results demonstrate that (RGERPPR) is a potential tumor-penetrating peptide.

The blood-brain barrier (BBB) and the blood-brain tumor barrier (BBTB) prevent drug and nano-drug delivery systems from entering the brain. However, ligand-mediated nano-drug delivery systems have significantly enhanced the therapeutic treatment of glioma. In this study we investigated the mechanism especially the integrity of liposomes and lipid disks while traversing the BBB and BBTB both and . Fluorophores (DiO, DiI and DiD) were loaded into liposomes and lipid disks to form Förster resonance energy transfer (FRET) nano-drug delivery systems. Using brain capillary endothelial cells as a BBB model, we show that liposomes and disks are present in the cytoplasm as their intact forms and traverse the BBB with a ratio of 0.68‰ and 1.67‰, respectively. Using human umbilical vein endothelial cells as BBTB model, liposomes and disks remained intact and traversed the BBTB with a ratio of 2.31‰ and 8.32‰ at 3 h. imaging and immunohistochemical results revealed that liposomes and disks could traverse the BBB and BBTB as intact forms. In conclusion, these observations explain in part the mechanism by which nano-drug delivery systems increase the therapeutic treatment of glioma.

Malignant glioma is usually accompanied by vigorous angiogenesis to provide essential nutrients. An effective glioma targeting moiety should include excellent tumor-cell homing ability as well as good neovasculature-targeting efficiency, and should be highly resistant to enzyme degradation in the bloodstream. The phage display-selected heptapeptide, the glioma-initiating cell peptide (GICP), was previously reported as a ligand for the VAV3 protein (a Rho-GTPase guanine nucleotide exchange factor), which is mainly expressed on glioma cells; the stabilized heptapeptide A7R has been shown to be the ligand of both vascular endothelial growth factor receptor 2 (VEGFR2) and neuropilin-1 (NRP-1), and has demonstrated good neovasculature-targeting ability. By linking A7R and GICP, a multi-receptor targeting molecule was obtained. The stability of these three peptides was evaluated and their targeting efficiency on tumor-related cells and models was compared. The ability of these peptides to cross the blood--tumor barrier (BTB) was also determined. The results indicate that the coupled Y-shaped peptide A7R-GICP exhibited improved tumor and neovasculature targeting ability and had higher efficiency in crossing the BTB than either individual peptide.

Lack of mucoadhesive properties is the major drawback to poloxamer 407 (F127)-basedhydrogels for mucosal administration. The objective of the present study was to construct a novel mucoadhesive and thermosensitivehydrogel drug delivery system based on an amino-functionalized poloxamer for vaginal administration. First, amino-functionalized poloxamer 407 (F127-NH) was synthesized and characterized with respect to its micellization behavior and interaction with mucin. Then using acetate gossypol (AG) as model drug, AG-loaded F127-NH-basedhydrogels (NFGs) were evaluated with respect to rheology, drug release,vaginal mucosal adhesion,intravaginal retention and local irritation after vaginal administration to healthy female mice. The results show that F127-NHis capable of forming a thermosensitivehydrogel with sustained drug release properties. An interaction between positively charged F127-NHand negatively charged mucin was revealed by changes in the particle size and zeta potential of mucin particles as well as an increase in the complex modulus of NFG caused by mucin.andfluorescence imaging and quantitative analysis of the amount of AG remaining in mouse vaginal lavage all demonstrated greater intravaginal retention of NFG than that of an unmodified F127-basedhydrogel. In conclusion, amino group functionalization confers valuable mucoadhesive properties on poloxamer 407.

The purpose of this study is to evaluate theretention capabilities of poloxamer-basedhydrogels for vaginal application with nonoxinol-9 as the model drug. Twohydrogel formulations, which contained 18% poloxamer 407 plus 1% poloxamer 188 (GEL1, relative hydrophobic) or 6% poloxamer 188 (GEL2, relative hydrophilic), were compared with respect to the rheological properties,hydrogel erosion and drug release. The vaginal retention capabilities of these hydrogel formulations were further determined in two small animal models, including drug quantitation of vaginal rinsing fluid in mice and isotope tracing withTc in rats. The two formulations exhibited similar phase transition temperatures ranging from 27 to 32 °C. Increasing the content of poloxamer 188 resulted in higher rheological moduli under body temperature, but slightly accelerated hydrogel erosion and drug release. When compared, GEL1 was eliminated significantly slower in rat vagina than GEL2, while the vaginal retention of these two hydrogel formulations behaved similarly in mice. In conclusion, increases in the hydrophilic content of formulations led to faster hydrogel erosion, drug release and intravaginal elimination. Rats appear to be a better animal model than mice to evaluate thehydrogel for vaginal application.

Objective To investigate the protective effect of Addie on cardiac injury induced by radiotherapy and chemotherapy in patients with cervical cancer.Methods 74 cases of cervical cancer were collected from the oncology department of Zhousha Hospital, those were treated with surgery and radiotherapy and chemotherapy according to postoperative staging and classification of cases.The patients were randomly divided into the experimental group and the control group, with 37 cases in each group.Control group received leukogenic and antiemetic treatment,the experimental group were given Addie injection 100 mL intravenous drip on the basis of the control group, one times per day,10 days as one courses, and two groups were all received 6 courses of treatment.Atthe end of treatment, the condition of heart function, left ventricular ejection fraction, left ventricular end diastolic diameter, 6 minutes walk test, myocardial enzymes, troponin T, C reactive protein /Barhel quality of life score index, EORTC-QLQ score and the incidence of adverse reactions were detected and compared with two groups.Results After treatment, the cardiac function of the experimental group was significantly better than that of the control group (P<0.05).After treatment,LVEDD of two groups decreased (P<0.05), LVEF, 6 minutes walk test distance increased (P<0.05),and LVEDD of experimental group was lower than control group (P<0.05), LVEF, 6 minutes walk test distance higher (P<0.05).After treatment, creatine kinase and creatine kinase levels were increased in two groups (P<0.05).Compared with the control group, the level of creatine kinase and creatine kinase in experimental group were higher(P <0.05).After treatment,the levels of troponin T and C reactive protein in two groups were decreased ( P <0.05 ) .Compared with the control group, the levels of troponin T and C reactive protein in experimental group were lower (P<0.05).After treatment,the scores of Barhel index and EORTC-QLQ score of two groups were significantly higher than before treatment, and the quality of life of the experimental group was significantly higher than that of control group ( P <0.05 ) .There was no significant difference in the incidence of adverse reactions between two groups.Conclusion Addie has an obvious protective effect on cardiac injury induced by radiotherapy and chemotherapy in patients with cervical cancer, and can improve the quality of life of patients.

Objective To investigate the protective effect of Shen Mai injection in the treatment of lung injury induced by radiotherapy in patients with advanced breast cancer. Methods 80 cases with lung injury induced by radiotherapy in patients with advanced breast cancer from our hospital from 2015.1 to 2016.5 were selected and randomly divided into 2 groups, 40 cases in control group were given routine treatment, 40 cases in the experimental group were treated based on the control group treated with Shenmai injection treatment, and 2 groups were treated for 4 weeks. The pulmonary function, T lymphocyte subsets, clinical symptoms, quality of life scores and clinical efficacy were observed before and after treatment in two groups. The results were analyzed by statistical software SPSS 19.0. Results Compared with before treatment, levels of FVC, FEV1 and TLC in 2 groups after treatment elevated, scores of respiratory symptoms, activities, and daily life effect decreased, levels of serum CD3+, CD4+, CD4+/CD8+elevated, levels of CD8+ decreased, and compared with the control group, levels of FVC, FEV1, TLC, CD3+, CD4+, CD4+/CD8+ in the experimental group were higher, scores of respiratory symptoms, activities, and daily life effect were lower, clinical effect rate was higher, the differences were statistically significant (P<0.05). Conclusion Shen Mai injection can effectively improve lung function and immunity, improve respiratory symptoms and improve the quality of life in patients with advanced breast cancer radiotherapy for lung injury, and has better clinical efficacy.